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Abstract
Background: FAK localization to focal adhesions is essential for its activation and function.
Localization of FAK is mediated through the C-terminal focal adhesion targeting (FAT) domain.
Recent structural analyses have revealed two paxillin-binding sites in the FAT domain of FAK. To
define the role of paxillin binding to each site on FAK, point mutations have been engineered to
specifically disrupt paxillin binding to each docking site on the FAT domain of FAK individually or
in combination.
Results: These mutants have been characterized and reveal an important role for paxillin binding
in FAK subcellular localization and signaling. One paxillin-binding site (comprised of α-helices 1 and
4 of the FAT domain) plays a more prominent role in localization than the other. Mutation of either
paxillin-binding site has similar effects on FAK activation and downstream signaling. However, the
sites aren't strictly redundant as each mutant exhibits phosphorylation/signaling defects distinct
from wild type FAK and a mutant completely defective for paxillin binding.
Conclusion: The studies demonstrate that the two paxillin-binding sites of FAK are not redundant
and that both sites are required for FAK function.
Background
Focal adhesion kinase is a non-receptor tyrosine kinase
that plays an important role in mediating essential cellu-
lar processes, such as cell growth, survival, and migration.
FAK knockout mice exhibit embryonic lethality with
defects in mesoderm, notochord, somites and the heart
[1]. In addition, these embryos exhibit shortened ante-
rior-posterior axes and vascular defects. Similar pheno-
types have been described for fibronectin null mice [2]
Paxillin null mice also share some of the phenotypes
observed in fak-/- embryos including truncated anterior-
posterior axes and developmental defects in the heart and
somites [3]. In accordance with the phenotypes of these
mice, FAK plays an important role in mediating integrin
signaling following cell adhesion to extracellular matrix
proteins, e.g. fibronectin, and paxillin is an important
physiological binding partner of FAK [4,5].
When integrins bind to the extracellular matrix they clus-
ter on the cell surface resulting in the assembly of protein
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complexes, which include FAK, at these sites of adhesion.
Cell adhesion induces FAK autophosphorylation at Y397,
which creates docking sites for proteins with SH2
domains. The major binding partners recruited into com-
plex with FAK following Y397 phosphorylation include
Src, PI3 kinase, Grb7, and phospholipase C-γ [4]. Src sub-
sequently phosphorylates other tyrosine residues in FAK.
Y576 and Y577 are located within the activation loop of
FAK and phosphorylation of these sites by Src regulates
catalytic activity [6]. Src can also phosphorylate Y861 and
Y925 in the C-terminus of FAK [7,8]. Phosphorylation of
Y861 is induced by VEGF stimulation and promotes the
formation of a complex between FAK and the αvβ5
integrin in endothelial cells [9]. Phosphorylation of Y925
may promote dissociation of FAK from focal adhesions
[10]. By creating a binding site for the SH2 domain of
Grb2, Y925 phosphorylation may be important for activa-
tion of ERK [8]. Grb2 binding to Y925 also recruits
dynamin to focal adhesions, which is important for focal
adhesion disassembly [11]. Thus, these Src-dependent
phosphorylation events play an important role in regula-
tion of FAK signaling downstream of integrin attachment.
The recruitment of FAK to focal adhesions is essential for
its regulation by integrin-dependent adhesion to the
extracellular matrix [12]. The C-terminal focal adhesion
targeting (FAT) domain is responsible for the discrete
localization of FAK to focal adhesions and this domain
binds to two focal adhesion associated proteins, paxillin
and talin [13-15]. Both of these proteins have been pro-
posed to function in the localization of FAK to focal adhe-
sions. Paxillin is a scaffolding protein containing multiple
domains that mediate protein-protein interactions,
including five N-terminal LD motifs, four C-terminal LIM
domains, and SH2 and SH3 domain binding sites [16].
The second (LD2) and fourth LD motifs (LD4) of paxillin
have been identified as FAK-binding sites and each of
these sites binds to FAK with similar affinity [17,18]. Pax-
illin-/- cells exhibit reduced localization of FAK to focal
adhesions and reduced phosphorylation of FAK [3,19].
These results suggest that paxillin binding may function in
the regulation of FAK activity, in addition to its proposed
role in regulating localization.
Recent reports have used both NMR and crystallographic
approaches to determine that the structure of the C-termi-
nal FAT domain of FAK is a four-helix bundle [20-23].
Additional studies have also revealed the structure of the
FAT domain of FAK in complex with peptides mimicking
the LD2 peptide of paxillin [24,25]. The striking finding
from these studies was the identification of two paxillin-
binding sites on the FAT domain of FAK. This finding is
particularly intriguing, given the presence of two FAK-
binding sites in the N-terminus of paxillin. The two paxil-
lin-binding sites in the FAT domain are structurally simi-
lar and consist of a surface exposed hydrophobic patch,
adjacent to a series of basic residues. One paxillin-binding
site lies at the interface of α-helices 2/3 and the other at
the interface of α-helices 1/4 and thus the two sites are on
opposite sides of the four-helix bundle. While evidence
suggests that the LD2 peptide of paxillin interacts with
both of these sites with similar affinity [24], the results of
a paramagnetic labeling experiment suggests that the pax-
illin LD4 peptide has a preference for one site over the
other [25].
These studies raise an interesting question of whether the
two paxillin-binding sites of FAK are simply redundant
interaction surfaces that strengthen the association
between these two proteins, or alternatively, whether pax-
illin binding to each site might mediate a distinct func-
tion. To address these important questions, site-directed
mutagenesis was used to disrupt binding to the α-helix 2/
3 paxillin-binding site (E949A/K956A/R963A or EKR) or
to the α-helix 1/4 paxillin-binding site (I937A). Combin-
ing these mutations together (E949A/K956A/R963A/
I937A or EKR/I937A) completely abolished paxillin bind-
ing as demonstrated in vitro by GST pulldown and in vivo
by co-immunoprecipitation as previously reported [24].
These mutants have been characterized to determine the
role of paxillin binding to each site individually in the reg-
ulation of FAK.
Results
Paxillin has two FAK binding sites and mutants of paxillin
that disrupt binding to FAK have been previously
described [18]. Recent studies have revealed that FAK also
has two binding sites for paxillin. The I937A mutation is
in helix 1 and destroys paxillin binding to the helix 1/4
binding site but retains paxillin binding to the helix 2/3
binding site (Fig. 1A)[24]. Conversely, the EKR mutations
are in helix 2 and abrogates binding to the helix 2/3 bind-
ing site, yet retains binding activity through the helix 1/4
binding site (Fig. 1A)[24]. To assess the ability of individ-
ual binding sites on paxillin and FAK to interact, a GST
pulldown approach was utilized. GST fusion proteins,
shown in Figure 1B, were used to bind to FAK variants
expressed in CE cells. The GST fusion proteins contained
the N-terminal portion of paxillin containing both FAK-
binding sites, i.e. LD 2 and LD 4 (GST-PaxN1C3). GST
fusion proteins with point mutations that disrupt FAK
binding to LD2 (D146A) or LD4 (D268A) were also used,
as well as a double mutant that abolishes FAK binding to
both LD2 and LD4 (D146A/D268A). Thus, these fusion
proteins contained a functional LD4 motif, a functional
LD2 motif and defective LD2/LD4 motifs respectively.
Fusion proteins, immobilized on glutathione beads, were
incubated with lysates of CE cells expressing FAK variants
and bound FAK assessed by western blotting. Wild type
FAK bound to the wild type recombinant paxillin, exhib-Journal of Molecular Signaling 2008, 3:1 http://www.jmolecularsignaling.com/content/3/1/1
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ited slightly reduced binding to recombinant paxillin with
one functional LD2 or LD4 motif, and bound poorly to
the double mutant (Fig. 1C, lanes 3–6). These observa-
tions are similar to published results using these paxillin
mutants [18]. The same trend is observed with the I937A
FAK mutant, i.e. reduced binding to the LD2 and LD4
mutants and poor binding to the double mutant (Fig. 1C,
lanes 11–14). This result suggests that the I937A mutant
(containing the intact helix 2/3 paxillin-binding site) can
bind to both the LD2 and LD4 FAK-binding sites of paxil-
lin. In contrast, the EKR FAK mutant exhibits a different
pattern of binding. This FAK mutant binds the wild type
paxillin fusion protein and shows reduced binding to the
paxillin mutant with a functional LD2 motif (Fig. 1C,
lanes 7 and 9). The EKR mutant binds very poorly to the
paxillin mutant with a functional LD4 motif and the dou-
In vitro binding of paxillin and FAK mutants Figure 1
In vitro binding of paxillin and FAK mutants. A) The I937A and EKR mutations are indicated on the structure of the FAT 
domain. The four α-helices are labeled. The paxillin binding sites are at the interface of α-helices 1/4 and the interface of α-hel-
ices 2/3. B) Schematic representation of paxillin and paxillin GST-fusion proteins used for the binding studies. White boxes 
denote the LD motifs. The proteins are designated WT, LD4, LD2 and none to reflect functional LD motifs in the constructs. 
The previously published designation of each construct is in parentheses. C) CE cells transfected with empty RCAS vector 
(lane 1), wild type FAK (lanes 2–6), EKR (lanes 7–10), or I937A (lanes 11–14) were lysed and 1 mg of lysate was used for bind-
ing assays. The functional paxillin binding site in each of the constructs is indicated in parentheses. Lysates were incubated with 
GST alone (lane 2), the WT (lanes 3, 7, 11), the LD4 (lanes 4, 8, 12), the LD2 fusion proteins (lanes 5, 9, 13), or with the pro-
tein lacking both LD2 and LD4 sites (none; lanes 6, 10, 14). The protein complexes were washed and bound FAK detected by 
Western blotting. D) GST-fusion proteins used in C were analyzed in parallel by SDS-PAGE and Coomassie staining to ensure 
equal loading.Journal of Molecular Signaling 2008, 3:1 http://www.jmolecularsignaling.com/content/3/1/1
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ble mutant (Fig. 1C, lanes 8 and 10). This result suggests
that the EKR mutant (containing the intact helix 1/4 pax-
illin-binding site) binds to the LD2 FAK-binding site of
paxillin, but binds very poorly to the LD4 FAK-binding
site of paxillin. These results reveal that the two paxillin-
binding sites of FAK do not interact with paxillin in pre-
cisely the same way. Both paxillin-binding sites of FAK
appear to bind to the LD2 motif of paxillin (Fig. 1C, lanes
9 and 13). However, the helix 2/3 binding site binds the
LD4 motif of paxillin (Fig. 1C, lane 12), while the helix 1/
4 binding site is defective (Fig. 1C, lane 8). Thus the LD4
motif preferentially associates with the interface of α-hel-
ices 2 and 3, whereas the LD2 motif can associate with
either paxillin-binding site.
The subcellular localization of FAT domain mutants was
assessed by immunofluorescence of exogenously
expressed protein. Initially, CE cells expressing exogenous
FAK using the RCAS retroviral vector were analyzed. Cells
were plated onto fibronectin-coated coverslips and
allowed to adhere overnight. Coverslips were fixed, per-
meabilized, and stained with a FAK polyclonal antibody
and FITC-anti-rabbit secondary antibody. The exogenous
proteins are expressed at high levels making it easy to dis-
tinguish their expression (Fig. 2A). Examples of cells
exhibiting focal adhesion localization of each of the FAK
mutants are shown in Figure 2B. To validate these find-
ings, a complimentary approach using GFP-tagged FAK
variants was used to assess localization. GFP fused to wild
type FAK or the FAK mutants were transiently expressed in
CE cells. At 24 hrs post-transfection, the cells were plated
onto glass-bottom dishes and 24 hours later, the cells
were viewed by epifluorescence and TIRF microscopy.
Each of the FAT domain mutants exhibited focal adhesion
localization by both epifluorescence (data not shown)
and TIRF microscopy (Fig. 2C). These experiments
revealed that mutants of FAK that disrupt paxillin binding
to either site on the FAT domain or to both sites can still
localize to focal adhesions. However, during the course of
imaging the transfected CE cells it was apparent that some
of the mutants were more difficult to find at focal adhe-
sions, suggesting there might be a quantitative difference
in efficiency of localization. To further investigate the sub-
cellular localization of these mutants, stable populations
of CHO cells expressing GFP-FAK fusion proteins at a sim-
ilar level as endogenous FAK protein were established
(Fig. 3A). Cells were plated on glass coverslips and
allowed to spread overnight before being fixed and
stained using an avian GFP antibody. Focal adhesions
were stained using a paxillin monoclonal antibody and a
rhodamine-labeled secondary antibody. Fixed cells were
imaged and paxillin staining was used to identify focal
adhesions. Cells were scored for co-localization of paxillin
and GFP staining, indicating FAK localization at these
sites. The results were expressed as percentage of cells
exhibiting focal adhesion localization of GFP-FAK (Fig.
3B). Like wild type FAK, the EKR FAK mutant was targeted
to focal adhesions in about 90% of the cells. The I937A
mutant was localized to focal adhesions in about 55% of
the cells, indicating that this paxillin-binding site may be
more important for focal adhesion targeting than the
other paxillin-binding site. Although some cells express-
ing the mutant EKR/I937A, which has defects in both pax-
illin-binding sites, exhibit focal adhesion localization of
the FAK mutant, the efficiency of targeting was severely
decreased compared to wild type FAK. These results indi-
Subcellular localization of FAK mutants Figure 2
Subcellular localization of FAK mutants. A) CE cells 
transfected with empty RCAS vector (mock) or RCAS con-
structs encoding wild type FAK or FAK mutants were lysed 
and 25 µg of lysate was blotted for FAK expression with BC4 
antibody. B) CE cells transfected with empty RCAS vector 
(mock) or RCAS encoding wild type FAK or FAK mutants 
were plated on fibronectin-coated coverslips overnight, then 
fixed and used for immunofluorescent imaging using the FAK 
BC4 antibody. C) CE cells transfected with GFP-fusion con-
structs of wild type FAK or mutants were visualized in live 
cells by TIRF microscopy.Journal of Molecular Signaling 2008, 3:1 http://www.jmolecularsignaling.com/content/3/1/1
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Quantification of focal adhesion localization Figure 3
Quantification of focal adhesion localization. A) CHO-K1 cells were transfected with the empty EGFP vector or GFP N-
terminally tagged versions of wild type or FAK mutants. Stably expressing populations were selected and lysed. Twenty-five µg 
of lysate was immunoblotted to examine FAK expression. Endogenous FAK and GFP-FAK are indicated. B) CHO-K1 cells sta-
bly expressing the EGFP vector alone, or GFP-FAK fusion proteins were plated on fibronectin coated coverslips overnight, 
then fixed and used for immunofluorescent staining with a GFP antibody. The cells were counterstained with a paxillin antibody 
to locate focal adhesions. GFP-positive cells were scored for GFP localization at focal adhesions. The data was analyzed using a 
one-way analysis of variance and the Dunnett post test (* denotes p < 0.01). C) CE cells transfected with GFP-FAK fusion pro-
teins were plated on fibronectin-coated coverslips overnight, then fixed and used for immunofluorescent staining with a GFP 
antibody. The cells were also stained with a paxillin antibody to facilitate identification of focal adhesions. A second example of 
GFP-E997A localized to focal adhesion is also shown (lower right panel).Journal of Molecular Signaling 2008, 3:1 http://www.jmolecularsignaling.com/content/3/1/1
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cate that although paxillin binding is not absolutely
required for FAK localization, this association does play
an important role in FAK's ability to localize to focal adhe-
sions.
Although the above experiments indicated that paxillin
plays a major role in the regulation of FAK targeting to
focal adhesions, the FAK mutant defective for paxillin
binding still correctly localized in approximately 10% of
cells. This mutant presented a suitable background for
additional mutagenesis studies to identify residues out-
side of the paxillin-binding regions of the FAT domain
that are important for FAK localization. Additional
alanine substitutions at conserved residues on the surface
of the FAT domain were made and the subcellular locali-
zation of the resulting mutants was assessed upon tran-
sient expression as GFP fusion proteins in CE cells. Using
this approach, E997 was identified as a residue important
for FAK localization to focal adhesions in the absence of
paxillin binding (Fig. 3C). This mutant was further ana-
lyzed by stable expression of the GFP fusion protein in
CHO cells. The E997A mutation in combination with the
EKR/I937A mutations resulted in a complete absence of
the FAK mutant from focal adhesions. However, the
E997A mutant in an otherwise wild type background, i.e.
with intact paxillin-binding sites, was able to localize to
focal adhesions nearly as well as wild type FAK (Fig. 3B
and 3C). This result indicates that E997 is important for
the localization of FAK to focal adhesions in the absence
of paxillin binding.
As FAK phosphorylation is important for its activation
and downstream signaling, and defects in FAK phosphor-
ylation were observed in paxillin null cells [3], the
mutants were characterized for phosphorylation defects.
Cell lysates were probed with phospho-specific antibodies
by Western blotting to assess the phosphorylation status
of different sites in FAK in CE cells growing in culture. At
the exposure shown in Fig. 4A, phosphorylation of endog-
enous FAK was barely detectable. The results indicate that
Y397 is phosphorylated comparably on wild type and
mutant FAK proteins (Fig. 4A). Since this site is the major
autophosphorylation site of FAK, this experiment indi-
cates that paxillin binding is not required for FAK auto-
phosphorylation. Phosphorylation of Y861, like that of
Y397, is not dependent upon paxillin binding as mutants
that disrupt binding to individual sites or both sites have
no effect on phosphorylation of Y861. In contrast, phos-
phorylation of Y576 and Y577 is dependent upon paxillin
binding. Both of these sites in the activation loop of the
kinase show reduced phosphorylation when paxillin
binding is disrupted (Fig. 4A). Mutants with a single func-
tional paxillin-binding site and the mutant lacking func-
tional paxillin binding sites exhibited similar reductions
in phosphorylation at these sites. Phosphorylation of FAK
was also measured from cells stimulated by cell adhesion
to fibronectin using phospho-specific antibodies. Note
that at these exposures the phosphorylation of endog-
enous FAK is detectable, despite the inability to see endog-
enous FAK protein in the blot (Fig. 4B, lanes 1 and 3). This
appears to be due to a higher stoichiometry of phosphor-
ylation of the endogenous protein than exogenously
expressed protein in this system (MDS, unpublished
observation). The results indicate that Y397 and Y861 are
phosphorylated in each of the mutants comparably to
wild type FAK following cell adhesion (Fig. 4B). Phospho-
rylation of Y576 and Y577 is dependent upon paxillin
binding following cell adhesion since phosphorylation
was reduced in mutants that disrupt paxillin binding to at
least a single paxillin-binding site in FAK.
Identification of defects in FAK phosphorylation Figure 4
Identification of defects in FAK phosphorylation. A) 
CE cells were transfected with the RCAS empty vector 
(mock) or RCAS encoding wild type FAK or FAK mutants. 
Subconfluent cells growing in culture were lysed and immu-
noblotted with the indicated phospho-specific antibodies. In 
parallel lysates were blotted for FAK expression as a loading 
control. B) Phosphorylation of FAK variants was examined in 
cells growing in culture (cul)(lanes 1, 4, 7, 10, 13), after incu-
bation in suspension for 30 minutes (sus)(lanes 2, 5, 8, 11, 
14), and after plating on fibronectin for 45 minutes 
(FN)(lanes 3, 6, 9, 12, 15). Twenty-five µg of lysate was ana-
lyzed by immunoblotting using phospho-specific antibodies. 
Lysates were also blotted for FAK as a loading control.Journal of Molecular Signaling 2008, 3:1 http://www.jmolecularsignaling.com/content/3/1/1
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To assess downstream signaling of the various FAK FAT
domain mutants, phosphorylation of FAK substrates was
measured as previously described [26]. Briefly, CE cells
expressing wild type or mutant forms of FAK were vanad-
ate treated to prevent dephosphorylation of cellular pro-
teins. FAK substrates p130CAS and paxillin were
immunoprecipitated from cell lysates. Immunoprecipi-
tated proteins were immunoblotted with a phosphotyro-
sine antibody, as shown in Figure 5. FAK mutants with a
single paxillin-binding site induced tyrosine phosphoryla-
tion of p130CAS (Fig. 5A) and paxillin (Fig. 5B), although
the levels of phosphorylation were reduced compared to
the levels seen upon expression of wild type FAK. The FAK
mutant with mutations at both paxillin-binding sites
failed to induce phosphorylation of p130CAS or paxillin.
These results indicate a role for paxillin binding in the
transmission of signals downstream of FAK.
Discussion
Recent structural analyses have revealed that FAK has two
binding sites for paxillin. This raises the question of
whether these binding sites are simply redundant,
whether they act in concert, or whether engagement of
distinct binding sites results in different outcomes. Site
directed mutagenesis was used to disrupt paxillin binding
to each individual binding site or to both binding sites
simultaneously on the FAK FAT domain to begin to
address these issues. Efficient localization of FAK to focal
adhesions could occur with a single functional paxillin-
binding site, although one binding site appeared more
important for localization than the other. Both paxillin-
binding sites appeared to work in concert to promote
maximal phosphorylation of activation site tyrosines in
FAK. Both binding sites were also required for maximal
phosphorylation of downstream substrates, although a
single binding site was sufficient to promote sub-optimal
substrate phosphorylation.
A report measuring NMR chemical shifts upon titration of
the FAT domain with synthetic paxillin peptides and par-
amagnetic labeling experiments suggested that the LD2
and LD4 motifs of paxillin bound differently [25]. The
LD4 motif exhibited a preference for the paxillin-binding
site between α-helices 2/3, while the LD2 motif exhibited
a preference for the other binding site between α-helices
1/4 [25]. Using recombinant fragments of paxillin, with
mutations impairing one or the other FAK-binding site, a
similar conclusion regarding LD4 motif binding was
drawn here, i.e. that the LD4 motif exhibits a preference
for binding to the α-helices 2/3 side of the FAT domain.
However, the results regarding LD2 motif binding are dis-
cordant. The results present herein demonstrate that the
LD2 motif of recombinant paxillin binds comparably to
both paxillin binding sites of the FAT domain, which is
consistent with other published results examining LD2
motif binding to the FAT domain. ITC analysis deter-
mined that the binding affinities of the two paxillin-bind-
ing sites on the FAT domain for a peptide mimicking the
LD2 motif of paxillin are similar, approximately 10 micro-
molar [24]. Further, ITC data suggested that the two bind-
ing sites were independent, as the binding isotherms for
the wild type FAT domain binding a paxillin-derived LD2
peptide could be fit well to a two-independent binding
site model. Consistent with this analysis, the I937A muta-
tion abolished binding of the LD2 peptide to one paxillin-
binding site and the EKR mutation abolished binding of
the LD2 peptide to the other paxillin-binding site. It was
therefore anticipated that the two binding sites would
contribute equally to binding of full-length paxillin. How-
ever, binding studies using recombinant GST-paxillin
fusion proteins and co-immunoprecipitation experiments
demonstrated substantially more paxillin binding to the
I937A mutant than to the EKR mutant [24]. Thus, the
integrity of the α-helices 2/3 paxillin-binding site of the
Phosphorylation of FAK substrates in vivo Figure 5
Phosphorylation of FAK substrates in vivo. CE cells 
transfected with empty RCAS vector (mock) or RCAS 
encoding wild type FAK or FAK mutants were left untreated 
(-) or treated with vanadate overnight prior to lysis (+). A) 
p130CAS was immunoprecipitated from 1 mg lysate and the 
immunoprecipitated protein was immunoblotted for phos-
photyrosine (upper panel) and p130CAS (bottom panel). B) 
Paxillin was immunoprecipitated from 1 mg lysate and the 
immunoprecipitated protein was immunoblotted for phos-
photyrosine (top panel) and paxillin (bottom panel).Journal of Molecular Signaling 2008, 3:1 http://www.jmolecularsignaling.com/content/3/1/1
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FAT domain of FAK is more important for the interaction
with full-length paxillin than the other binding site. This
observation is consistent with the hypothesis that the α-
helices 2/3 binding site can interact with both the LD2
and LD4 motifs of paxillin, whereas the α-helices 1/4
binding site associates preferentially with the LD2 motif.
Although paxillin binding is not absolutely required for
FAK subcellular localization, it is the major mechanism of
focal adhesion localization. When paxillin binding is
abolished, the FAK mutant localizes to focal adhesions
with about 10% efficiency relative to wild type FAK. Fur-
ther, the mutants disrupting individual paxillin binding
sites differed in their efficiency of localization. The EKR
mutant localized like wild type FAK, whereas the I937A
mutant was partially defective. This seems surprising con-
sidering that the EKR mutant exhibits reduced binding to
paxillin in an in vitro binding assay or by co-immunopre-
cipitation compared with the I937A mutant [24]. This
indicates that paxillin binding does not precisely correlate
with focal adhesion localization. For subcellular localiza-
tion of FAK, the paxillin-binding site comprised of α-hel-
ices 1/4 is more important than paxillin-binding site
comprised of α-helices 2/3.
Glutamic acid 997 was identified as an important residue
for localization in the absence of paxillin binding. Note
that this residue is on the α-helices 3/4 face of the FAT
domain and lies outside of the two LD motif-binding
sites. In the background of a FAK mutant that is defective
for paxillin binding, mutation of this residue to alanine
completely abolished focal adhesion localization, but in a
wild type FAK background, this mutation does not signif-
icantly affect focal adhesion localization. Binding to this
residue may represent a secondary, less efficient mecha-
nism by which FAK can be localized to focal adhesions in
the absence of paxillin binding. Talin is a focal adhesion
protein that has been reported to bind to the FAT domain
of FAK and has been suggested to function as a mecha-
nism for FAK subcellular localization [15,27]. It is possi-
ble that E997 is an important residue for the association
between FAK and talin. However, we have been unable to
test this hypothesis, as we have been unable to detect the
interaction between the FAT domain of FAK and talin by
co-immunoprecipitation, GST pulldown or direct binding
between purified recombinant proteins. Alternatively,
E997 might be important for interaction with another
binding partner and the E997A mutant might be a useful
tool for the identification of additional physiologically
relevant binding partners.
Phosphorylation of FAK is important for association with
binding partners and for maximal catalytic activity.
Results from paxillin null cells suggest paxillin binding is
essential for maximal FAK phosphorylation [3,19]. The
paxillin-binding defective FAK mutants have provided
additional insight. When paxillin binding is abolished
with the EKR/I937A mutant of FAK and focal adhesion
localization is dramatically reduced, the ability of FAK to
autophosphorylate on Y397 is not affected. Similarly,
phosphorylation of Y861, which is a Src substrate, is not
affected. However phosphorylation of Y576 and Y577,
the Src phosphorylation sites in the activation loop of
FAK, is impaired in this mutant. Several studies have indi-
cated that the Y861 Src phosphorylation site on FAK is reg-
ulated differently than phosphorylation of the other Src
sites on FAK, so this finding that Y576/Y577 and Y861 are
differentially affected is not completely surprising [28-
30]. Interestingly, mutants with defects in a single paxil-
lin-binding site show similar defects in phosphorylation
of Y576 and Y577, suggesting that engagement of both
paxillin-binding sites is required for maximal phosphor-
ylation of these sites. The fact that each of the paxillin-
binding mutants show similar defects in phosphorylation
of FAK indicates that phosphorylation of FAK at the acti-
vation loop sites does not precisely correlate with the abil-
ity of FAK to localize to focal adhesions. Paxillin binding
to both sites on FAK may be required to allow Src binding
to FAK, perhaps by tethering FAK to focal adhesions more
securely. However, as Y397 phosphorylation is not
altered, such a mechanism would indicate a defect in Src
recruitment downstream of FAK autophosphorylation. A
more likely scenario is that paxillin binding to both sites
on FAK may cluster FAK proteins, thus facilitating phos-
phorylation of FAK by associated Src molecules.
A paxillin mutant defective for FAK binding is defective
for tyrosine phosphorylation following adhesion and in
src-transformed fibroblasts [18]. Thus it was anticipated
that FAK mutants defective for paxillin binding would
exhibit defects in their ability to promote paxillin phos-
phorylation. These mutants exhibited a parallel defect in
p130CAS phosphorylation. The more severe defect in sub-
strate phosphorylation observed in cells expressing the
EKR/I937A mutant is likely due to the localization defect
exhibited by the mutant resulting in the spatial segrega-
tion of the kinase and its substrate. The defect in p130CAS
phosphorylation by I937A could partially reflect the
decreased localization of the FAK mutant, but as the EKR
mutant localizes correctly, its decreased ability to induce
p130CAS phosphorylation cannot be attributed to a
defect in localization. Instead, this defect correlates with
reduced activation loop phosphorylation and may reflect
reduced FAK activity and hence reduced substrate phos-
phorylation in vivo.
These findings provide interesting insight into how multi-
ple binding sites for paxillin contribute to FAK function,
but there is also a practical implication arising from these
studies. Aberrant FAK signaling is associated with patho-Journal of Molecular Signaling 2008, 3:1 http://www.jmolecularsignaling.com/content/3/1/1
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logical conditions, e.g. the development of some cancers
[31,32], and one experimental strategy to perturb FAK sig-
naling is exogenous expression of the C-terminal non-cat-
alytic domain, which functions as a dominant negative
mutant [33-35]. More efficacious strategies to inhibit FAK
signaling therapeutically would entail select inhibition of
the interaction of FAK with critical binding partners. Our
findings suggest that simultaneous disruption of both
paxillin-binding sites would be required for maximal
inhibition of FAK localization and function. Perhaps as
importantly these findings also suggest that partial atten-
uation of FAK function might be obtained by selectively
disrupting the interaction of paxillin with one of its two
binding sites in the FAT domain. Such a strategy might
allow attenuation of FAK signaling in target tissue without
ablation of FAK signaling in normal tissue, which may
reduce the deleterious effects of such therapeutic
approaches.
Conclusion
The main conclusions of this study are 1) a single func-
tional paxillin-binding site can target FAK to focal adhe-
sions, 2) both paxillin-binding sites are required to
promote maximal phosphorylation of activation site tyro-
sines in FAK and 3) both binding sites are required for
maximal phosphorylation of downstream substrates.
Methods
Molecular biology
FAK mutants were engineered using pBluescript-FAK or
pEGFP-EKR/I937A as a template. Point mutations were
engineered using the QuikChange mutagenesis kit (Strat-
agene, La Jolla CA). Sequence analysis was performed to
verify the intended point mutations and that no unin-
tended mutations were present. These analyses were per-
formed in the UNC-CH Genome Analysis Facility on a
model 3730 DNA Analyzer (Perkin Elmer, Applied Bio-
systems Division) using the ABI PRISM™ Dye Terminator
Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA
Polymerase, FS (Perkin Elmer, Applied Biosystems Divi-
sion). Full-length FAK cDNAs were subcloned into RCAS
A as described previously [36]. Full-length FAK cDNAs
were subcloned into pEGFP as described previously [37].
All subcloned constructs were verified by sequence analy-
sis.
Cells and viruses
Chicken embryo (CE) cells were prepared and maintained
as described previously [38]. These cells were transfected
using Lipofectamine PLUS (Life Technologies, Gaithers-
burg, MD) with RCAS A retroviral vectors encoding wild
type or mutant FAK proteins [24]. To address the regula-
tion of FAK phosphorylation in response to adhesion,
cells were trypsinized, washed in 0.5 mg/mL soybean
trypsin inhibitor (Sigma, St. Louis, MO) in PBS, held in
suspension for 30 minutes, and replated onto dishes
coated with fibronectin (50 µg/ml) for 45 minutes. In
order to enhance the phosphotyrosine content of cellular
proteins in some experiments, cells were treated with 50
µM sodium vanadate for 16 hrs prior to lysis [39].
CHO cells were maintained in DMEM containing 10%
FBS, 4 mM L-glutamine, 1 mM sodium pyruvate and 1%
non-essential amino acids. To generate stable populations
of CHO cells expressing GFP tagged constructs, the cells
were transfected with plasmids encoding wild type FAK or
mutants fused to GFP using Lipofectamine PLUS (Life
Technologies), followed by selection and maintenance in
1 mg/ml G418 (Gibco BRL). Populations of G418
selected CHO cells were then sorted by FACS to enrich for
GFP expression. Trypsinized CHO cells were washed once
in PBS then resuspended in 0.5 ml PBS. Flow cytometry
was performed on a Becton Dickinson FACScan interfaced
to a Cytomation, Inc. Cicero data acquisition system in
the UNC Flow Cytometry Facility.
Protein analysis
Cells were washed twice with PBS and lysed in modified
RIPA buffer (50 mM Tris [pH 7.3], 150 mM NaCl, 1% Tri-
ton X-100, 0.5% deoxycholate) containing protease and
phosphatase inhibitors. Protein concentrations were
determined with the bicinchoninic acid assay (Pierce,
Rockford, Ill.). The FAK phosphorylation site-specific
antibodies (Biosource International, Camarillo, CA) and
paxillin, p130CAS, and PY20 phosphotyrosine antibodies
(BD Biosciences, San Diego, CA) were purchased com-
mercially. The BC4 polyclonal antiserum has been
described previously [40]. Immunoprecipitations and
Western blotting were performed as previously described
[26].
Immunofluorescence
Glass coverslips were coated with 50 µg/mL bovine
plasma fibronectin (Sigma) in PBS for 1 hr at 37°C. Cells
were plated onto the coated coverslips and maintained at
37°C for 16 hr. Cells were fixed in 3.7% formaldehyde
and permeabilized with 0.5% Triton X-100. FAK was
detected using BC4 and rhodamine-conjugated anti-rab-
bit antibody (Jackson ImmunoResearch Labs). For co-
staining studies, a paxillin monoclonal antibody (BD Bio-
sciences) and rhodamine conjugated anti-mouse second-
ary antibodies (Jackson Labs) were used to visualize focal
adhesions while an avian GFP antibody (Chemicon Inter-
national, Temula, CA) and FITC anti-chicken secondary
antibodies (Jackson Labs) were used to detect GFP-tagged
proteins. Cells were visualized using a Leitz Orthoplan
fluorescence microscope, and images captured with a
Hamamatsu digital camera and Metamorph imaging soft-
ware (Universal Imaging Corporation, West Chester, PA).
Images were taken with identical exposure times. PaxillinJournal of Molecular Signaling 2008, 3:1 http://www.jmolecularsignaling.com/content/3/1/1
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staining was used to identify focal adhesions and cells
were scored for co-localization of paxillin and GFP stain-
ing, indicating FAK localization at these sites. The results
were expressed as percentage of cells exhibiting focal
adhesion localization of GFP-FAK to focal adhesions.
ANOVA analyses with Dunnett post-tests were performed
using GraphPad software (San Diego, CA) to identify sta-
tistically significant differences in localization efficiency.
For live cell imaging, EGFP N-terminally tagged forms of
wild type FAK or the FAK mutants were expressed in CE
cells using Lipofectamine PLUS (Invitrogen). At 24 hrs,
the transfected cells were plated in 35 mm glass bottom
dishes (MatTek, Ashland, MA) and incubated overnight at
37°C. At 48 hrs, cells were viewed using an Olympus IX81
microscope by epifluorescence and total internal reflec-
tion fluorescence (TIRF) microscopy.
Protein preparation and in vitro binding experiments
GST fusion proteins were expressed in E. coli and purified
as described [26]. Briefly, expression was induced with 0.1
mM isopropyl 1-thio-β-D-galactopyranoside, followed by
incubation for 2 hrs at 37°C. The bacteria were harvested
and sonicated in TETN buffer (1% Triton X-100, 20 mM
Tris [pH 8.0], 100 mM NaCl, 1 mM EDTA) plus protease
inhibitors (1 mM PMSF, 10 µg/mL leupeptin, 10 U/mL
aprotinin). Clarified supernatants were bound to glutath-
ione-agarose beads (Sigma) for 1 hr at 4°C, washed three
times with PBS, and resuspended in equal volumes PBS.
Fusion proteins were quantified by SDS/PAGE and
Coomassie blue staining. For binding experiments, 1 mg
of CE lysate was precleared by incubation with 100 µg of
GST bound to glutathione-agarose beads for 1 hr at 4°C,
then incubated with 25 µg GST fusion proteins immobi-
lized on beads for 2 hrs at 4°C. The beads were washed
twice with modified RIPA buffer, twice with PBS, eluted in
sample buffer, and analyzed by western blotting.
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